EW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Edwards Lifesciences Corp (EW) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong growth prospects in the TAVR market, positive analyst sentiment, and recent CMS proposal expanding market potential make it a favorable choice. Despite a lack of immediate trading signals and balanced congressional trading activity, the stock's long-term growth trajectory and bullish moving averages support the investment decision.
The stock's technical indicators show bullish moving averages (SMA_5 > SMA_20 > SMA_200), suggesting an upward trend. The RSI is neutral at 56.001, and the MACD histogram is negative but contracting, indicating potential stabilization. Key resistance levels are at 88.883 and 90.4, while support levels are at 83.97 and 82.453.
The CMS proposal to expand TAVR coverage to asymptomatic severe aortic stenosis is a significant positive catalyst, boosting Edwards Lifesciences' market potential. Analysts are optimistic about the company's ability to gain market share and achieve double-digit growth. Recent price target increases from analysts further support the stock's positive outlook.
The MACD histogram remains slightly negative, and the stock has a 50% chance of declining slightly (-1.11%) in the next day or week. Additionally, congressional trading activity is balanced, which does not provide strong confidence in insider sentiment.
Financial data for the latest quarter is unavailable. However, analysts have noted strong Q1 results, with double-digit TAVR growth momentum and raised revenue and EPS guidance. Management's long-term targets of 10% annual sales growth and margin expansion remain intact.
Analysts are generally bullish, with multiple firms raising price targets recently. Ratings include Outperform, Buy, and Market Perform, with price targets ranging from $85 to $110. Analysts highlight the company's growth potential in the TAVR market and other procedure categories, as well as its ability to expand market share and improve margins.
